Poland· PL-100124390
Xolair
A omalizumab product containing omalizumabum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Omalizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX05 (omalizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Omalizumab · ATC R03DX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of omalizumab costs, country by country.
Normalised to the WHO defined daily dose (16 mg), the median price runs from $0.26 in Czechia to $48.02 in Switzerland — a ×186 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Omalizumab · price per daily dose (16 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.02
- CZ Czechia$0.26
The record
At a glance
URPL (Poland)- Active substance
- Omalizumabum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- R03DX05
- ATC class
- Omalizumab
- Defined daily dose
- 16 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990340361
- gtin05909990708161
- gtin05909990708178
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for omalizumab.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Omalizumab · interactions on record
8 records
- 1 moderate
- 7 minor
Most severe, free to view
- Omacetaxine mepesuccinateL01XX40moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Omalizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumXolair 150 mgNovartis Europharm
- SpainXOLAIR 150 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLENovartis Europharm Limited
- United KingdomXolair 150mg powder and solvent for solution for injection vialsNovartis Pharmaceuticals UK Ltd
- IcelandXolairNovartis Europharm Limited*
- NorwayXolairNovartis
- SwedenXolair 150 mg Pulver och vätska till injektionsvätska, lösningNovartis Europharm Limited
- CzechiaOMLYCLOCelltrion Healthcare Hungary Kft., Budapest
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omlyclo, Xolair
- Liechtenstein · Omlyclo, Xolair
- Norway · Omlyclo, Xolair
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc026244-0395-4c84-9701-5662fc596a52 GET /v1/drugs/cc026244-0395-4c84-9701-5662fc596a52?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "150 mg",
"packaging": "05909990340361 ¦ Rpz ¦ EU/1/05/319/002 ¦ 29299\n1 fiol. 150 mg proszku ¦ 1 amp. 2 ml rozp.\n05909990708161 ¦ Rpz ¦ EU/1/05/319/003 ¦ 51110\n4 fiol. 150 mg proszku ¦ 4 amp. 2 ml rozp.\n05909990708178 ¦ Rpz ¦ EU/1/05/319/004 ¦ 51111\n10 fiol. 150 mg proszku ¦ 10 amp. 2 ml rozp.",
"substance": "Omalizumabum 150 mg",
"common_name": "Omalizumabum",
"pl_product_id": "100124390",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about omalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.